학술논문
Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk.
Document Type
article
Author
Tian, Yu; Kim, Andre E; Bien, Stephanie A; Lin, Yi; Qu, Conghui; Harrison, Tabitha A; Carreras-Torres, Robert; Díez-Obrero, Virginia; Dimou, Niki; Drew, David A; Hidaka, Akihisa; Huyghe, Jeroen R; Jordahl, Kristina M; Morrison, John; Murphy, Neil; Obón-Santacana, Mireia; Ulrich, Cornelia M; Ose, Jennifer; Peoples, Anita R; Ruiz-Narvaez, Edward A; Shcherbina, Anna; Stern, Mariana C; Su, Yu-Ru; van Duijnhoven, Franzel JB; Arndt, Volker; Baurley, James W; Berndt, Sonja I; Bishop, D Timothy; Brenner, Hermann; Buchanan, Daniel D; Chan, Andrew T; Figueiredo, Jane C; Gallinger, Steven; Gruber, Stephen B; Harlid, Sophia; Hoffmeister, Michael; Jenkins, Mark A; Joshi, Amit D; Keku, Temitope O; Larsson, Susanna C; Le Marchand, Loic; Li, Li; Giles, Graham G; Milne, Roger L; Nan, Hongmei; Nassir, Rami; Ogino, Shuji; Budiarto, Arif; Platz, Elizabeth A; Potter, John D; Prentice, Ross L; Rennert, Gad; Sakoda, Lori C; Schoen, Robert E; Slattery, Martha L; Thibodeau, Stephen N; Van Guelpen, Bethany; Visvanathan, Kala; White, Emily; Wolk, Alicja; Woods, Michael O; Wu, Anna H; Campbell, Peter T; Casey, Graham; Conti, David V; Gunter, Marc J; Kundaje, Anshul; Lewinger, Juan Pablo; Moreno, Victor; Newcomb, Polly A; Pardamean, Bens; Thomas, Duncan C; Tsilidis, Konstantinos K; Peters, Ulrike; Gauderman, W James; Hsu, Li; Chang-Claude, Jenny
Source
Journal of the National Cancer Institute. 114(8)
Subject
Language
Abstract
BackgroundThe use of menopausal hormone therapy (MHT) may interact with genetic variants to influence colorectal cancer (CRC) risk.MethodsWe conducted a genome-wide, gene-environment interaction between single nucleotide polymorphisms and the use of any MHT, estrogen only, and combined estrogen-progestogen therapy with CRC risk, among 28 486 postmenopausal women (11 519 CRC patients and 16 967 participants without CRC) from 38 studies, using logistic regression, 2-step method, and 2- or 3-degree-of-freedom joint test. A set-based score test was applied for rare genetic variants.ResultsThe use of any MHT, estrogen only and estrogen-progestogen were associated with a reduced CRC risk (odds ratio [OR] = 0.71, 95% confidence interval [CI] = 0.64 to 0.78; OR = 0.65, 95% CI = 0.53 to 0.79; and OR = 0.73, 95% CI = 0.59 to 0.90, respectively). The 2-step method identified a statistically significant interaction between a GRIN2B variant rs117868593 and MHT use, whereby MHT-associated CRC risk was statistically significantly reduced in women with the GG genotype (OR = 0.68, 95% CI = 0.64 to 0.72) but not within strata of GC or CC genotypes. A statistically significant interaction between a DCBLD1 intronic variant at 6q22.1 (rs10782186) and MHT use was identified by the 2-degree-of-freedom joint test. The MHT-associated CRC risk was reduced with increasing number of rs10782186-C alleles, showing odds ratios of 0.78 (95% CI = 0.70 to 0.87) for TT, 0.68 (95% CI = 0.63 to 0.73) for TC, and 0.66 (95% CI = 0.60 to 0.74) for CC genotypes. In addition, 5 genes in rare variant analysis showed suggestive interactions with MHT (2-sided P